L-5HTP in depression resistant to re-uptake inhibitors. An open comparative study with tranylcypromine.
L-5HTP and tranylcypromine were compared in an open, but controlled and cross-over study, in patients suffering from major depression; all were non-responders to several reuptake inhibitors, including oxaprotiline and fluvoxamine. After four unsuccessful sleep-deprivations, L-5HTP or tranylcypromine were given during four weeks in a crossover design. Of 17 patients given L-5HTP during both treatment periods, none responded, whereas of 26 patients treated with tranylcypromine, 15 responded. Thus, L-5HTP is not a therapeutically effective alternative in depressed patients who have not responded to reuptake inhibitors.
D006916:5-Hydroxytryptophan / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002230:Carbidopa / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D016666:Fluvoxamine; D005500:Follow-Up Studies; D006801:Humans; D008376:Maprotiline / Q000031:analogs & derivatives / Q000627:therapeutic use; D008875:Middle Aged; D010091:Oximes / Q000627:therapeutic use; D011897:Random Allocation; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D013237:Stereoisomerism; D014191:Tranylcypromine / Q000627:therapeutic use*
D010091:Oximes; D012702:Serotonin Antagonists; D008376:Maprotiline; D014191:Tranylcypromine; C027299:hydroxymaprotilin; D006916:5-Hydroxytryptophan; D002230:Carbidopa; D016666:Fluvoxamine